Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Improve therapeutic response through inhibition of endosome machinery in multiple myeloma

Yutong Wang, Liuting Chen, Yung-hsing Huang, Jin He, Li Bao, Yihui Fan, Pei Lin, Qing Yi, Jing Yang

Blood (2025) 146 (Supplement 1): 3917.

https://doi.org/10.1182/blood-2025-3917

Published: 2025

Journal Articles

Transition to IRD maintenance after DRD induction significantly deepens response in transplant-ineligible NDMM: A prospective multicenter study

Qiuqing Xiang, Minqiu Lu, Bin Chu, Lei Shi, Shan Gao, Lijuan Fang, Mengzhen Wang, Shuangnian Xu, Yan Zhu, Li Wang, Junnan Li, Hua Xue, Li Li, Tingting Duan, Ting Zhang, Li Bao

Blood (2025) 146 (Supplement 1): 4059.

https://doi.org/10.1182/blood-2025-4059

Published: 2025

Journal Articles

Is autologous hematopoietic stem cell transplantation as consolidation therapy superior to chemotherapy alone in newly diagnosed intermediate-high risk DLBCL patients?

Shuozi Liu, Lan Ma, Hui Liu, Jiefei Bai, Wenrong Huang, JunLi Chen, Li Bao, Shan Gao, Wanling Sun, Zhenling Li, Min Wang, Hongmei Jing

Blood (2025) 146 (Supplement 1): 1888.

https://doi.org/10.1182/blood-2025-1888

Published: 2025

Journal Articles

Pola-R-CHP in previously untreated low-risk (IPI 0-1) DLBCL: A nationwide multicenter retrospective study in China

Blood (2025) 146 (Supplement 1): 7229.

https://doi.org/10.1182/blood-2025-7229

Published: 2025

Journal Articles

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Blood (2025) 146 (Supplement 1): 5818.

https://doi.org/10.1182/blood-2025-5818

Published: 2025

Journal Articles

Does intensive consolidation confer a clinical advantage over continued less intensive therapy in elderly patients with Acute Myeloid Leukemia in first remission following azacitidine plus venetoclax induction?

Blood (2025) 146 (Supplement 1): 5162.

https://doi.org/10.1182/blood-2025-5162

Published: 2025

Journal Articles

SG301, a Novel Anti-CD38 Monoclonal Antibody, in Patients with Relapsed/Refractory Multiple Myeloma: A First-in-Human, Multicentre, Phase 1 Trial

Blood (2024) 144 (Supplement 1): 4746.

https://doi.org/10.1182/blood-2024-199381

Published: 2024

Journal Articles

A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 498.

https://doi.org/10.1182/blood-2024-193738

Published: 2024

Journal Articles

Comparison of Ixazomib, Lenalidomide Plus Dexamethasone (IRd) and Bortezomib, Lenalidomide Plus Dexamethasone (VRd) in Newly Diagnosed Multiple Myeloma in China

Wenjing Wang, Jing Li, Mengyuan Li, Xiao He, LI Bao, Xiaoqiong Tang, Hua Xue, Jianmei Xu, Liye Zhong, Peng Liu

Blood (2024) 144 (Supplement 1): 5159.

https://doi.org/10.1182/blood-2024-207888

Published: 2024

Journal Articles

In-Class Transition (iCT) of Proteasome Inhibitor-Based Therapy Prolongs Progression-Free Survival in High-Risk Myeloma Patients: A Real-World Chinese Cohort Study

Rong Fu, Hong Yu, Aijun Liu, Rui Hou, Zunmin Zhu, Junling Zhuang, Li Bao, Zhenling Li, Lihong Liu, Luoming Hua, Yanping Ma, Da Gao, ARong Jin, Xiaohui Suo, Wei Yang, Yuansong Bai, Deqiang Zheng, Wenming Chen

Blood (2024) 144 (Supplement 1): 7846.

https://doi.org/10.1182/blood-2024-209471

Published: 2024

Journal Articles

Efficacy and Safety of Zanubrutinib-Containing Regimens in Patients with Secondary CNS Relapse in Diffuse Large B-Cell Lymphoma

Li Bao, Kai HU, Xiaoyan Ke, Yutong Wang, Mengzhen Wang, Lei Shi, Kai Sun

Blood (2023) 142 (Supplement 1): 6095.

https://doi.org/10.1182/blood-2023-181041

Published: 2023

Journal Articles

Low Erythropoietin to Albumin Ratio in the Serum Predicts Less Reversibility of Renal Impairment with Poorer Prognosis in Multiple Myeloma

Kai Sun, Ying Liu, Yanliang Bai, Haoyan Wang, Mengzhen Wang, Yuan Chen, Li Bao

Blood (2023) 142 (Supplement 1): 6681.

https://doi.org/10.1182/blood-2023-182670

Published: 2023

Journal Articles

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Blood (2023) 142 (Supplement 1): 4754.

https://doi.org/10.1182/blood-2023-180736

Published: 2023

Journal Articles

Combination of Circulating Plasma Cells Enhances the Efficacy of R2-ISS Stage System for Risk Stratification of Newly Diagnosed Multiple Myeloma: A Single-Center Real-World Study

Bin Chu, Yutong Wang, Lei Shi, Kai Sun, Li Bao

Blood (2023) 142 (Supplement 1): 4740.

https://doi.org/10.1182/blood-2023-181006

Published: 2023

Journal Articles

Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Ixazomib, Pegylated Liposomal Adriamycin, and Dexamethasone(IDd) in Elderly Frail Newly Diagnosed Multiple Myeloma with GA Score ≥2: A Prospective Multicenter Study

Li Bao, Min-qiu Lu, Peng Liu, Yu-Tong Wang, Junling Zhuang, Mei Zhang, Zhongjun Xia, Zhenling Li, Ying Yang, Zhenyu Yan, Hongmei Jing, Wenming Chen, Hebing Zhou, Rong Fu, Yuping Gong, Wenrong Huang, Yongqing Zhang

Blood (2022) 140 (Supplement 1): 12564–12565.

https://doi.org/10.1182/blood-2022-168068

Published: 2022

Journal Articles

Validation of the Impede VTE Score for Prediction of Venous Thromboembolism in Chinese Patients with Multiple Myeloma: A Retrospective Cohort Study

Li Bao, Yu-Tong Wang, Min-qiu Lu, Junling Zhuang, Bin Chu, Lei Shi, Shan Gao, Li-juan Fang, Qiu-qing Xiang, Xi Liu, Yue-hua Ding, Kai Sun

Blood (2022) 140 (Supplement 1): 5146–5147.

https://doi.org/10.1182/blood-2022-168633

Published: 2022

Journal Articles

Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Blood (2022) 140 (Supplement 1): 10167–10169.

https://doi.org/10.1182/blood-2022-159361

Published: 2022

Journal Articles

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimen for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Blood (2022) 140 (Supplement 1): 12637–12639.

https://doi.org/10.1182/blood-2022-169057

Published: 2022

Journal Articles

Lenalidomide Versus Thalidomide or Bortezomib As Maintenance Regimens for Non-Transplant Patients with Multiple Myeloma: Multi-Center Real World Experience in China

Zhe Zhuang, Lei Shi, Ying Tian, Dongmei Zou, Ru Feng, Fei Dong, Yanping Ma, Hong Yu, Wei-wei Tian, Shuangjiao Liu, Liangming Ma, Rong Fu, Hongmei Jing, Hui Liu, Wanling Sun, Chen Wenming, Yin Wu, Li Bao, Junling Zhuang

Blood (2021) 138 (Supplement 1): 4728.

https://doi.org/10.1182/blood-2021-149502

Published: 2021

Journal Articles

Trial in Progress: A Perspective Study of Pan-Oral Triplet Regimen Pomalidomide, Ixazomib and Dexamethasone in Relapsed or Refractory Myeloma Patients

Miao Chen, Li Bao, Wenming Chen, Rong Fu, Rong Guo, Hongmei Jing, Hui Liu, Qinhua Liu, Yanping Ma, Xiuli SUN, Wei Wang, Yafei Wang, Xiaojing Yan, Jiang Qian, Junling Zhuang

Blood (2021) 138 (Supplement 1): 4783.

https://doi.org/10.1182/blood-2021-148237

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Improve therapeutic response through inhibition of endosome machinery in multiple myeloma

Transition to IRD maintenance after DRD induction significantly deepens response in transplant-ineligible NDMM: A prospective multicenter study

Is autologous hematopoietic stem cell transplantation as consolidation therapy superior to chemotherapy alone in newly diagnosed intermediate-high risk DLBCL patients?

Pola-R-CHP in previously untreated low-risk (IPI 0-1) DLBCL: A nationwide multicenter retrospective study in China

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Does intensive consolidation confer a clinical advantage over continued less intensive therapy in elderly patients with Acute Myeloid Leukemia in first remission following azacitidine plus venetoclax induction?

SG301, a Novel Anti-CD38 Monoclonal Antibody, in Patients with Relapsed/Refractory Multiple Myeloma: A First-in-Human, Multicentre, Phase 1 Trial

A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma

Comparison of Ixazomib, Lenalidomide Plus Dexamethasone (IRd) and Bortezomib, Lenalidomide Plus Dexamethasone (VRd) in Newly Diagnosed Multiple Myeloma in China

In-Class Transition (iCT) of Proteasome Inhibitor-Based Therapy Prolongs Progression-Free Survival in High-Risk Myeloma Patients: A Real-World Chinese Cohort Study

Efficacy and Safety of Zanubrutinib-Containing Regimens in Patients with Secondary CNS Relapse in Diffuse Large B-Cell Lymphoma

Low Erythropoietin to Albumin Ratio in the Serum Predicts Less Reversibility of Renal Impairment with Poorer Prognosis in Multiple Myeloma

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Combination of Circulating Plasma Cells Enhances the Efficacy of R2-ISS Stage System for Risk Stratification of Newly Diagnosed Multiple Myeloma: A Single-Center Real-World Study

Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Ixazomib, Pegylated Liposomal Adriamycin, and Dexamethasone(IDd) in Elderly Frail Newly Diagnosed Multiple Myeloma with GA Score ≥2: A Prospective Multicenter Study

Validation of the Impede VTE Score for Prediction of Venous Thromboembolism in Chinese Patients with Multiple Myeloma: A Retrospective Cohort Study

Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimen for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Lenalidomide Versus Thalidomide or Bortezomib As Maintenance Regimens for Non-Transplant Patients with Multiple Myeloma: Multi-Center Real World Experience in China

Trial in Progress: A Perspective Study of Pan-Oral Triplet Regimen Pomalidomide, Ixazomib and Dexamethasone in Relapsed or Refractory Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only